Sector
PharmaceuticalsOpen
₹1,212Prev. Close
₹1,205.8Turnover(Lac.)
₹16,251.39Day's High
₹1,215Day's Low
₹1,196.852 Week's High
₹1,21052 Week's Low
₹567.75Book Value
₹156.19Face Value
₹1Mkt Cap (₹ Cr.)
1,21,356.85P/E
35.29EPS
34.16Divi. Yield
0.25Zydus Lifesciences will produce the Valsartan Tablets at its formulation manufacturing facility located in Ahmedabad SEZ - II, Gujarat.
Last week, Zydus Lifesciences received two observations from the USFDA regarding its transdermal manufacturing site in the SEZ at Ahmedabad.
Zituvimet XR is intended as an adjunct to diet and exercise to help improve glycemic control in adults with type 2 diabetes mellitus.
The OAI classification is the most severe of the three possible classifications assigned by the US FDA
Following this development, company’s counter slipped nearly 3% to an intraday low of ₹1,150.05 per piece on NSE.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 100.6 | 101.2 | 102.4 | 102.4 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 15,615.9 | 13,538.2 | 13,138.1 | 12,642.1 |
Net Worth | 15,716.5 | 13,639.4 | 13,240.5 | 12,744.5 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 7,981.9 | 7,780 | 6,347.4 | 5,809.9 |
yoy growth (%) | 2.59 | 22.56 | 9.25 | 79.83 |
Raw materials | -2,870.2 | -2,351.4 | -1,951.7 | -1,695.7 |
As % of sales | 35.95 | 30.22 | 30.74 | 29.18 |
Employee costs | -1,204.9 | -1,147.3 | -1,077.4 | -826 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 1,483.2 | 1,876 | 1,609.7 | 1,497.2 |
Depreciation | -478.7 | -451.1 | -428.9 | -293.1 |
Tax paid | -306 | -212.3 | -204.1 | -406.4 |
Working capital | 607.49 | 991.9 | 1,239 | 1,462.2 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 2.59 | 22.56 | 9.25 | 79.83 |
Op profit growth | -16.91 | 62.23 | -13.55 | 412.7 |
EBIT growth | -16.88 | 5.6 | 18.09 | 138.95 |
Net profit growth | -41.88 | 4.48 | 29.52 | 64.79 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 19,021.5 | 16,877.8 | 14,827.6 | 14,125 | 13,812.1 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 19,021.5 | 16,877.8 | 14,827.6 | 14,125 | 13,812.1 |
Other Operating Income | 525.9 | 359.6 | 282.3 | 278.5 | 441 |
Other Income | 307.1 | 186.6 | 2,583.1 | 45.6 | 113.9 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,665.8 | 130.91 | 3,99,537.26 | 867.6 | 0.81 | 5,536.99 | 98.75 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,205.8 | 35.29 | 1,21,311.57 | 1,405.2 | 0.25 | 3,172.6 | 156.19 |
Cipla Ltd CIPLA | 1,500.05 | 32.61 | 1,21,119.62 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Divis Laboratories Ltd DIVISLAB | 4,547 | 76.67 | 1,20,781.57 | 531 | 0.66 | 2,259 | 507.93 |
Dr Reddys Laboratories Ltd DRREDDY | 6,853.2 | 26.69 | 1,14,348.41 | 1,034.8 | 0.58 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Pankaj R Patel
Managing Director
Sharvil P Patel
Director
Mukesh M Patel
Independent Director
Nitin Raojibhai Desai
Independent Director
Dharmishta N Rawal
Independent Director
Apurva S Diwanji
Executive Director
Ganesh N Nayak
Independent Director
Bhadresh K Shah
Company Sec. & Compli. Officer
Dhaval N Soni
Independent Director
Akhil A. Monappa
Independent Director
Upasana Konidela.
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Zydus Lifesciences Ltd
Summary
Zydus Lifesciences Ltd. (Formerly known as Cadila Healthcare Ltd.) is one of the leading innovation driven pharmaceutical companiesin India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing,marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, includingbiosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products. The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh.Founded by the Late Promoter, Mr. Ramanbhai B. Patel, the Company was incorporated in May, 1995 and converted into a Public Limited Company in July, 1996. The Companys operation includes pharmaceuticals, which includes human formulations, veterinary formulations and bulk durgs, diagnostics, herbal products, skin care products and OTC products. In the year 1996, the Company made a strategic alliance with Gulin Pharma of China and launched Falcigo in India, which is an anti-malarial segment. In May 2000, the company acquired formulation business of Recon Ltd, which strengthens the company in the southern market. In the year 2001, they acquired German Remedies which was the largest M&A in the Indian Pharmaceutical sector and in the same year, they entered into a joint venture with US based Onconova for collaborative research
Read More
The Zydus Lifesciences Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1206.05 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Zydus Lifesciences Ltd is ₹121356.85 Cr. as of 26 Jul ‘24
The PE and PB ratios of Zydus Lifesciences Ltd is 35.29 and 7.72 as of 26 Jul ‘24
The 52-week high/low is the highest and lowest price at which a Zydus Lifesciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Zydus Lifesciences Ltd is ₹567.75 and ₹1210 as of 26 Jul ‘24
Zydus Lifesciences Ltd's CAGR for 5 Years at 39.26%, 3 Years at 25.81%, 1 Year at 93.94%, 6 Month at 63.72%, 3 Month at 26.76% and 1 Month at 12.51%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.